LAVA Therapeutics Announces Pricing of Initial Public Offering
25 March 2021 - 11:55AM
LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company
focused on applying its expertise in bispecific gamma-delta T cell
engagers to transform cancer therapy, today announced the pricing
of its initial public offering of 6,700,000 common shares at a
public offering price of $15.00 per share. In addition, LAVA has
granted the underwriters a 30-day option to purchase up to an
additional 1,005,000 common shares at the initial public offering
price, less underwriting discounts and commissions. All of the
shares are being offered by LAVA. The shares are expected to begin
trading on the Nasdaq Global Select Market on March 25, 2021 under
the ticker symbol “LVTX.”
Gross proceeds of the offering, before deducting
underwriting discounts and commissions and other offering expenses
payable by LAVA, are expected to be $100.5 million. The offering is
expected to close on March 29, 2021, subject to the satisfaction of
customary closing conditions.
J.P. Morgan, Jefferies and SVB Leerink are acting
as joint book-running managers for the offering. Kempen & Co is
acting as lead manager for the offering.
The registration statement relating to these
securities became effective on March 24, 2021. The offering will be
made only by means of a prospectus, copies of which may be obtained
from J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by
telephone at (866) 803-9204, or by email at
prospectus_eqfi@jpmchase.com; Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, or by telephone at (877) 821-7388 or by email at
prospectus_department@Jefferies.com; or SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at (800) 808-7525, ext. 6105, or by email at
syndicate@svbleerink.com.
This press release shall not constitute an offer to
sell or the solicitation of an offer to buy, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements,” including, without
limitation, statements regarding LAVA’s expectations regarding the
commencement of trading of its shares on the Nasdaq Global Select
Market and the completion and timing of the closing of offering.
Forward-looking statements are based on LAVA’s current expectations
and are subject to inherent uncertainties, risks and assumptions
that are difficult to predict. Factors that could cause actual
results to differ include, but are not limited to, risks and
uncertainties related to the satisfaction of customary closing
conditions and the completion of the offering. These and other
risks and uncertainties are described more fully in the section
titled “Risk Factors” in the final prospectus related to the
offering to be filed with the Securities and Exchange Commission.
Forward-looking statements contained in this press release are made
as of this date, and LAVA undertakes no duty to update such
information except as required under applicable law.
Company Contact:
IR@lavatherapeutics.com
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Mar 2023 to Mar 2024